Tirzepatide 10 mg Vial: Reconstitution and Dosing Chart
How much bacteriostatic water to add to a 10 mg vial of Tirzepatide, the concentration you get, and a full dose-to-units chart.
- Vial size
- 10 mg
- With 2 mL water
- 5 mg/mL
- common choice
- 10 units contain
- 0.5 mg
- at 2 mL, U-100
- Whole vial
- 200 units
- 2 mL on a U-100 scale
How much water to add
Bacteriostatic water only changes the concentration, not the amount of Tirzepatide in the vial. More water means more units per dose (easier to read), less water means fewer.
| Water added | Concentration | 10 units contain | 1 mg is | Whole vial |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 1 mg | 10 u | 100 u |
| 2 mL | 5 mg/mL | 0.5 mg | 20 u | 200 u |
| 2.5 mL | 4 mg/mL | 0.4 mg | 25 u | 250 u |
| 3 mL | 3.333 mg/mL | 0.333 mg | 30 u | 300 u |
Calculator and full dosing table
Preset to the 10 mg vial. Change any value; the table below the result updates with it.
- Concentration
- 5 mg/mL
- Doses per vial
- 2
- Weeks (1 dose/wk)
- 2
100 units (1 mL) on a 1 mL U-100 syringe: 5 mg from a 10 mg vial + 2 mL water (Tirzepatide).
Dosing table for a 10 mg vial
Syringe units (U-100) for each dose, by how much bacteriostatic water you add.
| Dose | 1 mL water | 2 mL water | 2.5 mL water | 3 mL water |
|---|---|---|---|---|
| 1 mg | 10 | 20 | 25 | 30 |
| 2.5 mg | 25 | 50 | 62.5 | 75 |
| 5 mg | 50 | 100 | 125 | 150 |
| 7.5 mg | 75 | 150 | 187.5 | 225 |
| 10 mg | 100 | 200 | 250 | 300 |
How the math works
Concentration is the vial's milligrams divided by the water you add. Volume to draw is your dose divided by that concentration. On a U-100 syringe, 1 mL is 100 units, so units = mL × 100.
5 mg ÷ 5 mg/mL = 1 mL
1 mL × 100 = 100 units
Trial doses behind the 10 mg vial figures
The 72-week obesity trial compared 5 mg, 10 mg and 15 mg of tirzepatide with placebo.[3]
10 mg: weekly doses and syringe units
10 mg tirzepatide vial at 1 / 2 / 3 mL of water (10 / 5 / 3.33 mg/mL), per sourced dose, with doses per vial and units at 1 / 2 / 3 mL: 2.5 mg: 4 weekly doses, no remainder; 25 / 50 / 75 units. 5 mg: 2 weekly doses, no remainder; 50 / 100 / 150‡ units. 10 mg: 1 weekly dose, no remainder; 100 / 200‡ / 300‡ units. 15 mg: the vial holds 0.67 of one dose. († marks a 10 mg tirzepatide reading under 5 units, hard to measure accurately; ‡ marks one over the 100 units a 1 mL U-100 syringe holds.)
Calculated from vial mg 10; water mL 1, 2, 3; units per mL 100; doses mg 2.5, 5, 10, 15; rows dose mg 2.5, doses 4, remainder mg 0, units 25, 50, 75; dose mg 5, doses 2, remainder mg 0, units 50, 100, 150; dose mg 10, doses 1, remainder mg 0, units 100, 200, 300. Formula: doses = floor(vialMg / doseMg); units = doseMg x waterMl / vialMg x 100
Measuring check for the 10 mg vial: 1 mL (10 mg/mL) spans 25 to 100 units, all within 5 to 100; 2 mL (5 mg/mL) spans 50 to 200 units, some over 100 units; 3 mL (3.33 mg/mL) spans 75 to 300 units, some over 100 units. For tirzepatide at 10 mg, every sourced dose is readable between 5 and 100 units at 1 mL.
Calculated from vial mg 10; doses mg 2.5, 5, 10; readable range units 5, 100. Formula: units = doseMg x waterMl / vialMg x 100, checked against 5 and 100
Is 10 mg a labelled tirzepatide strength?
Zepbound's label lists a multi-dose vial at 10 mg/2.4 mL (4.17 mg/mL), with a 0.6 mL dose volume.[4]
Dissolving 10 mg in 2.4 mL gives 4.17 mg/mL against the labelled 4.17 mg/mL, and the labelled 2.5 mg dose is a 0.6 mL draw, which is 60 units on a U-100 syringe.
Calculated from vial mg 10; label total mL 2.4; label dose mL 0.6; label dose mg 2.5; label conc mg per mL 4.17; units per mL 100. Formula: 10 / 2.4 = 4.17 mg/mL; 0.6 mL x 100 = 60 units
Single-dose pens and vials are labelled at 10 mg/0.5 mL, a one-injection presentation.[4]
The labelled 10 mg/0.5 mL product is 20 mg/mL, so the full 10 mg sits in a 50-unit volume.
Calculated from dose mg 10; volume mL 0.5; units per mL 100. Formula: 10 / 0.5 = 20 mg/mL; 0.5 x 100 = 50 units
The multi-dose vial leaflet says the vial contains 4 doses, with a dose taken weekly.[4]
Listed price for 10 mg
The price dataset has 29 single-vial listings at 10 mg with a median of $90.00, which works out to $9.00 per mg; listings ranged from $39.00 to $220.50 when checked on 2026-10-02.
Calculated from source our price listings dataset; vial mg 10; listings 29; median 90; min 39; max 220.5; checked 2026-10-02. Formula: median / vialMg = 90.0 / 10 = 9.00 per mg
Common questions
How much water goes in a 10 mg vial of Tirzepatide?
That choice only changes the concentration. With 2 mL, a 10 mg vial is 5 mg/mL; with 1 mL it is 10 mg/mL. Less water means fewer units per dose and harder-to-read marks for small doses.
How many units is 1 mg from a 10 mg vial?
With 2 mL of water, 1 mg is 20 units on a U-100 syringe. With other water amounts, see the table.
How many doses are in a 10 mg vial?
Divide the vial size by the dose (in the same unit). The calculator on this page shows the number of whole doses for any dose you pick.
How much bacteriostatic water for a 10 mg tirzepatide vial?
The water volume only sets the strength: 10 mg of tirzepatide in 1, 2 or 3 mL is 10, 5 or 3.33 mg/mL, which is 100, 50 or 33 mcg per syringe unit.
Calculated from vial mg 10; water mL 1, 2, 3; units per mL 100. Formula: mg/mL = 10 / mL; mg per unit = (mg/mL) / 100
What is the tirzepatide 10mg dosage?
A placebo-controlled diabetes trial gave tirzepatide once a week at 5, 10 or 15 mg.[5]
More on Tirzepatide
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 4ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 5Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2021PMID 34186022Accessed 2 Oct 2026
Found an error? Report a correction.